Who owns TRDA?
Institutional ownership of Entrada Therapeutics Inc. from Form 13F, Q2 2026
129 institutional managers reported holding Entrada Therapeutics Inc. (TRDA) in Form 13F filings for Q2 2026, with 29,445,455 shares worth $217M. The largest reported holder was Baker Bros. Advisors LP. Managers that filed both quarters added a net 3,974,963 shares (+15.6%). 27 opened new positions and 16 sold out.
- Funds holding
- 129
- Value held
- $217M
- New / sold out
- 27 / 16
- Net shares, same filers
- +15.6%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of TRDA
Share of 13F holdings is each fund's shares as a share of the 29,445,455 TRDA shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Merck & Co., Inc. New+$12.8M
- MPM Bioimpact LLC New+$9.2M
- AQR Capital Management LLC Added+$4.6M
- JPMorgan Chase & Co Added+$3.7M
- Nantahala Capital Management, LLC Added+$3.3M
- Millennium Management LLC Added+$1.8M
- BlackRock, Inc. Added+$1.7M
- Citadel Advisors LLC Added+$1.3M
- Quantinno Capital Management LP Added+$867K
- Gsa Capital Partners LLP New+$648K
Biggest sellers in Q2 2026
- TCG Crossover Management, LLC Trimmed-$9.0M
- Jones Hill Capital LP Sold out-$4.7M
- Acuta Capital Partners, LLC Sold out-$1.1M
- Nuveen, LLC Trimmed-$875K
- Marshall Wace, LLP Sold out-$679K
- BNP Paribas Financial Markets Trimmed-$634K
- Wellington Management Group LLP Trimmed-$591K
- Woodline Partners LP Trimmed-$518K
- Jane Street Group, LLC Sold out-$470K
- D. E. Shaw & Co., Inc. Trimmed-$343K
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $48.6M and sold $22.7M; 55 added and 31 trimmed.
Schedule 13D and 13G filings on TRDA
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2025-11-25TCG Crossover GP I, LLC SCHEDULE 13G filed by Entrada Therapeutics Inc.Schedule 13G
- 2025-02-14JANUS HENDERSON GROUP PLC SCHEDULE 13G filed by Entrada Therapeutics Inc.Schedule 13G
- 2025-02-04BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
Questions about TRDA ownership
- Who owns TRDA stock?
- 129 institutional investment managers reported TRDA positions in their Form 13F filings for Q2 2026, holding 29,445,455 shares worth $217M in total. Baker Bros. Advisors LP reported the largest position.
- Are funds buying or selling TRDA?
- In Q2 2026, 27 managers opened new TRDA positions, 55 added, 31 trimmed and 16 sold out. Managers that filed in both quarters added a net 3,974,963 shares.
- How current is this TRDA institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to TRDA by CUSIP. Options are left out. TRDA news and filings · TRDA insider trades · Top funds